Type 2 Diabetes Mellitus Completed Phase 1 Trials for Empagliflozin (DB09038)

Also known as: T2DM / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Type Two / Type Two Diabetes Mellitus / NIDDM / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus Non-insulin-dependent / Type 2 Diabetes / Diabetes, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Type 2 Diabetes (T2D) / Diabetes Mellitus´╝îType 2 / Diabetes Mellitus. Type 2 / Diabetes Mellitus Type 2 / Diabetes Mellitus Type-2 / Type-2 Diabetes Mellitus / Diabetes Mellitus 2 Type / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus, Type 2 (T2DM) / T2DM (Type 2 Diabetes Mellitus) / Type 2 Diabetes Mellitus (T2D) / Diabetes Mellitus, Type 2 / Type-2 Diabetes / Diabetes Type 2 / Type 2 Diabetes (T2DM) / Type II Diabetes / Diabetes, Type II / Type-II Diabetes Mellitus / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / Diabetes Type II / Type II; Diabetes / Diabetes Mellitus Type II / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02121483Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes MellitusTreatment
NCT01907113Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal ImpairmentTreatment
NCT01924767Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 TabletsTreatment
NCT01581658Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 DiabetesTreatment
NCT01316341Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes MellitusTreatment
NCT01276288Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesTreatment
NCT01211197Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on BioavailabilityTreatment
NCT005585714 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 DiabetesTreatment